Skip to content

Author

A. V. van Bodegraven

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Switching standard dosed intravenous to subcutaneous infliximab leads to similar drug exposure in inflammatory bowel disease patients independent of concomitant immunosuppressants (SHUFFLE study).

AIMS Subcutaneous (SC) flat-dose infliximab (IFX) biosimilar offers potential advantages over intravenous (IV) weight-based dosing. Prospective pharmacokinetic data and clinical outcomes in inflammatory bowel disease (IBD) are scarce, since drug approval was primarily based on a rheumatoid-arthritis study population co...

Lieke M. J. van de Ven-van Dinter, M. Romberg-Camps, D. Wong et al. · 1 citation
Open access Oct 2026

Genome-wide analysis of genetic modifiers of Crohn’s disease and ulcerative colitis risk in response to tobacco smoking

Summary Background Gene-environment interactions (GxE) are fundamental for understanding the mechanisms of human diseases. Tobacco smoking is of particular interest for Inflammatory bowel disease (IBD), as it worsens Crohn’s disease (CD) but protects against ulcerative colitis (UC). Here, we systematically examined the...

Jing-Jing Bai, R. Gacesa, J. Björk et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.